Edition:
United States

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

10.49USD
17 Aug 2018
Change (% chg)

$-0.31 (-2.87%)
Prev Close
$10.80
Open
$10.80
Day's High
$10.85
Day's Low
$10.48
Volume
16,897
Avg. Vol
64,192
52-wk High
$21.25
52-wk Low
$6.31

Latest Key Developments (Source: Significant Developments)

Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58
Monday, 12 Mar 2018 07:15am EDT 

March 12 (Reuters) - Syros Pharmaceuticals Inc ::SYROS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES.Q4 LOSS PER SHARE $0.58.Q4 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.ANNOUNCED APPOINTMENT OF JOSEPH J. FERRA AS CHIEF FINANCIAL OFFICER.SYROS PHARMA - BELIEVES CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO ENABLE CO TO FUND PLANNED OPERATING EXPENSE, CAPEX INTO 2020.  Full Article

Syros Announces Appointment Of Joseph J. Ferra As Chief Financial Officer
Monday, 12 Mar 2018 07:00am EDT 

March 12 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES APPOINTMENT OF JOSEPH J. FERRA AS CHIEF FINANCIAL OFFICER.SYROS PHARMACEUTICALS INC - ‍FERRA MOST RECENTLY SERVED AS MANAGING DIRECTOR AND CO-HEAD OF HEALTHCARE INVESTMENT BANKING AT JMP SECURITIES​.  Full Article

Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte
Wednesday, 31 Jan 2018 09:41am EST 

Jan 31 (Reuters) - Incyte Corp ::SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​.SYROS PHARMACEUTICALS - ‍PURSUANT TO AMENDMENT INCYTE AGREED TO BUY 125,656 SHARES OF CO'S COMMON STOCK FOR $1.2 MILLION IN CASH IN PRIVATE PLACEMENT​.  Full Article

Syros Announces 2018 Strategic Priorities And Expected Milestones
Monday, 8 Jan 2018 08:01am EST 

Jan 8 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES.ON TRACK TO REPORT CLINICAL DATA ON SY-1425 COMBINATIONS AND SY-1365.CO HAD ABOUT $81.9 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPT 30, 2017.EXPECTS TO BE ABLE TO FUND ANTICIPATED OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2019.  Full Article

Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Incyte Corp ::INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT.INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​.INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​.INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS.INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​.INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES.INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES.INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425
Tuesday, 2 Jan 2018 08:01am EST 

Jan 2 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS.SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS' ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425.SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT.SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​.  Full Article

Syros Pharma Q3 loss per share $0.53
Wednesday, 8 Nov 2017 08:01am EST 

Nov 8 (Reuters) - Syros Pharmaceuticals Inc :Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones.Q3 loss per share $0.53.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.  Full Article

SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425
Thursday, 5 Oct 2017 08:01am EDT 

Oct 5 (Reuters) - Syros Pharmaceuticals Inc ::SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS.SYROS PHARMACEUTICALS INC - DATA FROM TRIAL SUPPORT POTENTIAL CLINICAL UTILITY OF BIOMARKER TEST FOR PATIENT SELECTION.SYROS PHARMACEUTICALS INC - EXPECTS TO PRESENT INITIAL PHASE 2 CLINICAL DATA FOR SY-1425 AT ASH ANNUAL MEETING.  Full Article

Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing
Friday, 29 Sep 2017 05:04pm EDT 

Sept 29 (Reuters) - Syros Pharmaceuticals Inc :Syros Pharmaceuticals says on Sept 28 board appointed Nancy Simonian, co's president and CEO, as company's principal financial officer - SEC Filing.  Full Article

Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​
Monday, 11 Sep 2017 07:01am EDT 

Sept 11 (Reuters) - Syros Pharmaceuticals Inc :Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​.  Full Article

BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58

* SYROS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES